Colombia's National Institute of Food and Drug Monitoring (INVIMA), announced that it has reduced from 4.5 months (135 days) to 2 months (60 days) the processing time for the evaluation and approval of a clinical research human study protocol involving an investigational drug. INVIMA announced this change on its website on April 12, 2016, and also stated that it would achieve this time reduction by improving the efficiency of internal processes without compromising the quality of the evaluation of the study protocol.
Read MoreMarca País, Procolombia's division in charge of managing Colombia's country brand abroad, has signed an alliance with Interventional Concepts, a leading clinical development firm in Miami, FL USA with an office in Colombia and focused on conducting clinical trials in Colombia (www.interventionalconcepts.net), to work together to position Colombia as the premier destination in Latin America to conduct clinical trials. Colombia is able to provide the biopharma and medical device industries with a high enrollment rate, regulatory efficiency by the Instituto Nacional de Vigilancia de Medicamentos (INVIMA), competitive costs, highly qualified and motivated bilingual investigators and boasting an ideal geographical location with fast and direct airline connectivity from the major centers of innovation in the U.S. and Europe
Read More